| __timestamp | Catalyst Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 10117774 | 1271353000 |
| Thursday, January 1, 2015 | 11801342 | 1620577000 |
| Friday, January 1, 2016 | 11369941 | 2052295000 |
| Sunday, January 1, 2017 | 11375237 | 2075142000 |
| Monday, January 1, 2018 | 19919204 | 2186100000 |
| Tuesday, January 1, 2019 | 18842752 | 3036600000 |
| Wednesday, January 1, 2020 | 16496715 | 2735000000 |
| Friday, January 1, 2021 | 16936000 | 2908100000 |
| Saturday, January 1, 2022 | 19789000 | 3592500000 |
| Sunday, January 1, 2023 | 93150000 | 4439000000 |
| Monday, January 1, 2024 | 5132000000 |
Cracking the code
In the competitive world of biotechnology, investment in research and development (R&D) is a key driver of innovation. Over the past decade, Regeneron Pharmaceuticals, Inc. has consistently outpaced Catalyst Pharmaceuticals, Inc. in R&D spending. In 2023, Regeneron's R&D expenses soared to approximately $4.4 billion, marking a 250% increase since 2014. In contrast, Catalyst's R&D investment, while growing, reached around $93 million in 2023, a significant leap from its 2014 figure but still dwarfed by Regeneron's commitment.
This disparity highlights Regeneron's strategic focus on innovation, which has been pivotal in its development of groundbreaking therapies. Meanwhile, Catalyst's more modest investment reflects its niche focus within the industry. As the biotech landscape evolves, these investment trends will likely shape the future of medical advancements and market leadership.
R&D Insights: How Merck & Co., Inc. and Regeneron Pharmaceuticals, Inc. Allocate Funds
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Summit Therapeutics Inc.
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and Axsome Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc. or TG Therapeutics, Inc.: Who Invests More in Innovation?
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Viking Therapeutics, Inc.
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and ImmunityBio, Inc.
Regeneron Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Invests More in Innovation?
R&D Insights: How Regeneron Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc.
R&D Spending Showdown: Catalyst Pharmaceuticals, Inc. vs ImmunityBio, Inc.
Analyzing R&D Budgets: Catalyst Pharmaceuticals, Inc. vs Xencor, Inc.